New targeted therapy provides survival benefit in KRAS G12C-mutated lung cancer
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib […]
Che
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib […]Che
New targeted therapy provides survival benefit in KRAS G12C-mutated lung cancer
Copyright © 2025